Septerna (SEPN) CEO Finer received 400,000 Stock Option (Right to Buy)
Insider transactions reported
Jeffrey Finer (Chief Executive Officer at Septerna Inc., SEPN) reported that they received 400,000 Stock Option (Right to Buy) on Feb 6, 2026.
- Reporting person
- Finer Jeffrey
- Role
- Chief Executive Officer
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Feb 6, 2026 | Grant or award (A) | Stock Option (Right to Buy)On 400,000 Common Stock1 | +400,000 | - | - | 400,000 direct |
Holdings before and after
- Stock Option (Right to Buy): 0 to 400,000 direct
Footnotes from the filing
- 1. 2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Finer report in this SEPN Form 4?
Jeffrey Finer (Chief Executive Officer at Septerna Inc., SEPN) reported that they received 400,000 Stock Option (Right to Buy) on Feb 6, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for SEPN
Across the 10 sessions after earlier SEPN headlines, the stock closed higher 5 times and lower 5 times, with a median move of 2.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SEPN | SPY |
|---|---|---|---|
| Feb 11, 2026 | Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | -1.3% | -0.0% |
| Feb 10, 2026 | Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting | +0.4% | -0.3% |
| Jan 9, 2026 | Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer | -1.7% | +0.7% |
| Dec 19, 2025 | Raymond James initiated coverage on Septerna with a new price target | +7.4% | +0.6% |
| Dec 17, 2025 | Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference | +1.2% | -1.1% |
| Dec 15, 2025 | Truist initiated coverage on Septerna with a new price target | +6.8% | -0.2% |
Earlier insider filings at SEPN
- Feb 11, 2026SEC Form 4 filed by Chief Legal Officer Wilson Mark Andrew
- Nov 14, 2025SVP, Drug Discovery Long Daniel D. sold $63,223 worth of shares (3,501 units at $18.06), decreasing direct ownership by 4% to 92,911 units (SEC Form 4)
- Sep 29, 2025SEC Form 4 filed by Director Gottesdiener Keith Michael
- Aug 19, 2025SVP, Biological Sciences Klein Uwe exercised 23,008 shares at a strike of $4.10 (SEC Form 4)
- Aug 11, 2025SEC Form 4 filed by Chief People Officer Shaikhly Samira
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2024
Follow SEPN and get a push notification the moment its next story breaks.